COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Profitability Analysis including gross margin, operating margin, net margin, return on assets, return on equity, return on invested capital. Compare profitability against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Profitability Analysis - Compare Against 2127.T

Comparison against 2127.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.

Return on Equity (ROE)

3.81%

ROE of 3.81% while 2127.T has zero. Bruce Berkowitz would confirm if minor profitability translates into a competitive edge.

Return on Assets (ROA)

1.19%

ROA of 1.19% while 2127.T has zero. Walter Schloss would see if this modest profit advantage can be scaled.

Return on Capital Employed (ROCE)

4.24%

ROCE of 4.24% while 2127.T is zero. Bruce Berkowitz would verify if partial profitability can be accelerated.

Gross Profit Margin

20.77%

Gross margin below 50% of 2127.T's 65.02%. Michael Burry would watch for cost or pricing crises.

Operating Profit Margin

2.57%

Operating margin below 50% of 2127.T's 46.57%. Michael Burry would investigate whether this signals deeper issues.

Net Profit Margin

1.66%

Net margin below 50% of 2127.T's 23.68%. Michael Burry would suspect deeper competitive or structural weaknesses.

Select Chart Metric: